OpenLegislation

Regulation 50F Other applications including paediatric indicationsF1

(1)

This regulation applies in relation to an application to which neither regulation 50A nor 50E applies and which is—

(a)

an application for a F2UKMA(UK)(Category 1) for a relevant medicinal product which includes a paediatric indication; or

(b)

an application to include a paediatric indication in an existing UKMA(GB) F3or a UKMA(UK)(Category 1).

(2)

The applicant making an application to which this regulation applies must include in the application details of the measures intended to ensure the follow up of efficacy and of possible adverse reactions to the paediatric use of the medicinal product.

Annotations

Textual amendments

F1

Regs. 50A-50J inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 53 (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 40(a)-(g)); 2020 c. 1, Sch. 5 para. 1(1)

F2

Words in reg. 50F(1)(a) substituted (1.1.2025) by The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 30(a)

F3

Words in reg. 50F(1)(b) inserted (1.1.2025) by The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 30(b)